As a highly specialized shock-absorbing connective tissue, articular cartilage (AC) has very limited self-repair capacity after traumatic injuries, posing a heavy socioeconomic burden. Common clinical therapies for small- to medium-size focal AC defects are well-developed endogenous repair and cell-based strategies, including microfracture, mosaicplasty, autologous chondrocyte implantation (ACI), and matrix-induced ACI (MACI). However, these treatments frequently result in mechanically inferior fibrocartilage, low cost-effectiveness, donor site morbidity, and short-term durability. It prompts an urgent need for innovative approaches to pattern a pro-regenerative microenvironment and yield hyaline-like cartilage with similar biomechanical and biochemical properties as healthy native AC. Acellular regenerative biomaterials can create a favorable local environment for AC repair without causing relevant regulatory and scientific concerns from cell-based treatments. A deeper understanding of the mechanism of endogenous cartilage healing is furthering the (bio)design and application of these scaffolds. Currently, the utilization of regenerative biomaterials to magnify the repairing effect of joint-resident endogenous stem/progenitor cells (ESPCs) presents an evolving improvement for cartilage repair. This review starts by briefly summarizing the current understanding of endogenous AC repair and the vital roles of ESPCs and chemoattractants for cartilage regeneration. Then several intrinsic hurdles for regenerative biomaterials-based AC repair are discussed. The recent advances in novel (bio)design and application regarding regenerative biomaterials with favorable biochemical cues to provide an instructive extracellular microenvironment and to guide the ESPCs (e.g. adhesion, migration, proliferation, differentiation, matrix production, and remodeling) for cartilage repair are summarized. Finally, this review outlines the future directions of engineering the next-generation regenerative biomaterials toward ultimate clinical translation.
Research and development (R & D) of new drugs is a core engine driving medical progress and plays a crucial role in shaping human health and well-being. Challenges to the conventional drug discovery and development (DDD) pipeline include high cost, long duration, and unsatisfactorily high drug attrition rates. Recently, artificial intelligence (AI) and organoids/organs-on-chips (OoCs) have emerged as revolutionary toolboxes for potentially transforming therapeutic development. By analyzing large-scale datasets and complicated biological networks, AI promises to significantly impact modern drug innovation. Organoids/OoCs are emerging in vitro biological models that mimic the essential characteristics of human organs and tissues, offering potentially unparalleled physiological relevance and predictive power for in vitro disease modeling and pharmaceutical development. Over the past few years, several AI- or/and organoids/OoCs-discovered drugs have entered clinical trials, signaling the dawn of a new era of DDD. Notably, utilizing AI and organoids/OoCs simultaneously combines the best of both worlds and represents an innovative strategy to potentially expedite DDD. In this Perspective, we briefly introduce the general concepts of AI and organoids/OoCs, explore their state-of-the-art applications in DDD, and discuss why and how their synergistic impacts can revolutionize the R & D of new drugs. We also address current limitations and propose potential solutions to propel this innovative approach forward.